Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia by Chongqing Precision Biotech for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia is under clinical development by Chongqing Precision Biotech...
Data Insights
Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia by Chongqing Precision Biotech for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia is under clinical development by Chongqing Precision Biotech...